Literature DB >> 23883224

Periodic MRI lung volume assessment in fetuses with congenital diaphragmatic hernia: prediction of survival, need for ECMO, and development of chronic lung disease.

Anna Walleyo1, Angelika Debus, Sven Kehl, Christel Weiss, Stefan O Schönberg, Thomas Schaible, Karen A Büsing, K Wolfgang Neff.   

Abstract

OBJECTIVE: The purpose of the study was to investigate the ability to predict survival, need for extracorporeal membrane oxygenation (ECMO), and incidence of chronic lung disease in patients with congenital diaphragmatic hernia in the context of a classification into three different times of gestation (< 28, 28-32, and > 32 weeks) by assessing the ratio between observed and expected MRI fetal lung volume.
MATERIALS AND METHODS: The data analysis included 226 fetuses with congenital diaphragmatic hernia. MRI was performed at different times of gestation with a T2-weighted HASTE sequence. Receiver operating characteristic curve analysis was performed to investigate the prognostic value of assessment of the ratio between observed and expected MRI fetal lung volumes at different stages of fetal growth.
RESULTS: For all reviewed times of gestation, the ratio between observed and expected MRI fetal lung volumes had almost equivalent statistically significant differences for neonatal survival (p ≤ 0.0029), need for ECMO therapy (p ≤ 0.0195), and development of chronic lung disease (p ≤ 0.0064). Results with high prognostic accuracy for early and for medium and late times in gestation also were obtained. Receiver operating characteristic analysis showed the highest area under the curve (≥ 0.819) for neonatal survival.
CONCLUSION: In patients with congenital diaphragmatic hernia, the relation between observed and expected MRI fetal lung volume is a valuable prognostic parameter for predicting neonatal mortality, morbidity represented by the development of chronic lung disease, and the need for ECMO therapy in early gestation (< 28 weeks) as well as later gestation with no statistically significant differences.

Entities:  

Mesh:

Year:  2013        PMID: 23883224     DOI: 10.2214/AJR.12.8655

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

Review 1.  Why do we need more data on MR volumetric measurements of the fetal lung?

Authors:  Erika Rubesova
Journal:  Pediatr Radiol       Date:  2016-01-29

Review 2.  Congenital diaphragmatic hernia.

Authors:  Amy R Mehollin-Ray
Journal:  Pediatr Radiol       Date:  2020-11-30

3.  Management of Congenital Diaphragmatic Hernia in Newborn - Paradigm Shift and Ethical Issues.

Authors:  Sushmita Nitin Bhatnagar; Yogesh Kumar Sarin
Journal:  Indian J Pediatr       Date:  2017-06-16       Impact factor: 1.967

4.  Fetal-MRI prenatal diagnosis of severe bilateral lung hypoplasia: alveolar capillary dysplasia case report.

Authors:  Salvatore Zirpoli; Alice Marianna Munari; Mariangela Rustico; Gaetano Bulfamante; Gianluca Lista; Luigina Spaccini; Claudia Cesaretti
Journal:  J Prenat Med       Date:  2016 Jul-Dec

Review 5.  Extracorporeal Membrane Oxygenation in Congenital Diaphragmatic Hernia.

Authors:  Neysan Rafat; Thomas Schaible
Journal:  Front Pediatr       Date:  2019-08-08       Impact factor: 3.418

Review 6.  The role of magnetic resonance imaging in the diagnosis and prognostic evaluation of fetuses with congenital diaphragmatic hernia.

Authors:  Ilaria Amodeo; Irene Borzani; Genny Raffaeli; Nicola Persico; Giacomo Simeone Amelio; Silvia Gulden; Mariarosa Colnaghi; Eduardo Villamor; Fabio Mosca; Giacomo Cavallaro
Journal:  Eur J Pediatr       Date:  2022-07-07       Impact factor: 3.860

7.  Circulating microRNAs are associated with Pulmonary Hypertension and Development of Chronic Lung Disease in Congenital Diaphragmatic Hernia.

Authors:  Marisol Herrera-Rivero; Rong Zhang; Stefanie Heilmann-Heimbach; Andreas Mueller; Soyhan Bagci; Till Dresbach; Lukas Schröder; Stefan Holdenrieder; Heiko M Reutter; Florian Kipfmueller
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.